We have been working in inflammation for over 20 years and brought our first inflammation medicine to market in 2020. We are guided by the science and driven by the challenging to find new, innovative treatments for patients with chronic and debilitating conditions. In our approach to combatting inflammatory diseases we have a commitment to match yours; to make a difference. While there are still unmet needs we bring an unstoppable resolve to be part of the solution.
This site has been developed as an information sharing and resource hub specifically for healthcare professionals. As you scroll through the pages you will find information about who Galapagos are, our work in inflammation and specifically Rheumatoid Arthritis and Inflammatory Bowel Diseases and science and innovation and product information.
{{ calendar.eventHourMin}} ({{ calendar.timezone}})
{{calendar.eventDescription}}
{{ calendar.eventHourMin}} ({{ calendar.timezone}})
{{calendar.eventDescription}}
Galapagos’ core research areas are inflammatory, fibrotic, and kidney diseases, where our clinical activity is focused across several indications.
GALAPAGOS and the GALAPAGOS logo are registered or pending trademarks of Galapagos
NV.
© Galapagos Biopharma Sweden AB.
Vasagatan 7, 101 23 Stockholm, Sweden, VAT: SE559311454801. All rights reserved.
SE--JY-202203-00002
© Copyright 2021 Galapagos NV
You are about to leave this website and will be redirected to an external website. We are not responsible of that external website’s content. By continuing, you confirm that you have taken note of this.